MDS-141: The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study
Jacqueline S Garcia1, Andrew H Wei2, Uma Borate3, Chun Yew Fong4, Maria R Baer5, Florian Nolte6, Pierre Peterlin7, Joseph Jurcic8, Meagan Jacoby9, Wan-Jen Hong10, Uwe Platzbecker11, Olatoyosi Odenike12, Ilona Cunningham13, Ying Zhou14, Martin Dunbar14, Jason G Harb14, Relja Popovic14, Poonam Tanwani14, Sathej Gopalakrishnan15, Johannes Wolff14
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
2Department of Haematology, Alfred Hospital and Monash University, Melbourne, Australia
3Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
4Olivia Newton John Cancer Research Institute, Austin Health, Melbourne, VIC, Australia
5Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA
6Department of Hematology and Oncology, Charité University Hospital, Campus Benjamin Franklin, Berlin, Germany
7Hematology Department, Nantes University Hospital, Nantes, France
8Myelodysplastic Syndromes Center, Columbia University Medical Center, Columbia University, New York, NY, USA
9Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA
10Genentech Inc., South San Francisco, CA, USA.
11Medical Clinic and Policlinic 1, Hematology and Cellular therapy, University Hospital Leipzig, Germany
12University of Chicago Medicine and Comprehensive Cancer Center, Chicago, IL, USA
13Concord Clinical School, University of Sydney, Sydney, Australia
14AbbVie Inc., North Chicago, IL, USA
15AbbVie Deutschland GmbH & Co KG, Germany
Thông tin
Thông tin xuất bản
Clinical Lymphoma, Myeloma and Leukemia
Tập 20
S315-S316
Thông tin tác giả